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Introduction
The WNT/β-catenin signaling pathway, traditionally well-known as a regulator of embryonic development, tissue homeostasis and carcinogenesis, has recently been identified as an important endogenous regulator of hepatic drug metabolism in mouse liver, where the activity of this particular pathway determines hepatic zonation of cytochrome P450 (CYP) expression (Loeppen et al., 2005; Hailfinger et al., 2006; Sekine et al., 2006; Braeuning and Schwarz, 2010; Braeuning et al., 2011a; Schreiber et al., 2011) and is also critically involved in the regulation of CYP transcription in response to exposure to xenobiotic agonists of a number of nuclear receptors (Braeuning et al., 2009; Ganzenberg et al., 2013; Vaas et al., 2014) . Lipidand xenobiotic-sensing nuclear receptors pregnane X-receptor (PXR, NR1I2), the constitutive androstane receptor (CAR, NR1I3), and the aryl hydrocarbon receptor (AhR), together with the liver-enriched transcription factor peroxisome proliferator-activated receptor α (PPARα, NR1C1) form networks of transcription factors that coordinately regulate hepatic expression of the majority of drug-metabolizing CYPs, phase II enzymes and transporters in response to xenobiotic exposure (Handschin and Meyer, 2005; Pascussi et al., 2008; Pelkonen et al., 2008 ; Thomas et al., 2013) . Recent research elucidated extensive crosstalk between these receptors and other nuclear receptors and transcription factors, linking xenobiotic metabolism to the homeostasis of lipids, bile acids, glucose and other endogenous processes (Moreau et al., 2008; Gao and Xie, 2012) . For WNT/β-catenin signaling in general, it has been observed that activation of the pathway in murine liver cells stimulates the expression of most CYPs and augments their inducibility by xenobiotic agonists of nuclear receptors in vivo and in vitro. Further studies link the β -catenin pathway to elevated expression of some CYPs in human hepatoblastoma (Schmidt et al., 2011) and primary human hepatocytes (PHH), underlining the relevance of these findings also for humans. In particular it was found that the WNT/β-catenin pathway activation induces the expression of CYP2E1, CYP1A2, and AhR, but not of CYP3A4, hepatocyte nuclear factor-4α, or PXR in PHHs (Gerbal-Chaloin et al.,
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5 2014). However, so far there are no systematic data available on the impact of the WNT/β-catenin pathway on the regulation of basal or xenobiotic-induced CYP gene expression and activities in human cells.
Furthermore, while the interactions of signal transduction through β -catenin and the drugsensing receptors PXR, CAR and AhR have been studied previously, a potential interaction of β -catenin with PPARα remains to be established. This nuclear receptor acts as a lipid sensor to control the expression of gene networks involved in lipid and energy homeostasis, adipocyte differentiation, and inflammatory responses (Lalloyer and Staels, 2010; Wahli and Michalik, 2012) . Recently, we demonstrated that PPARα directly regulates the transcription of CYP3A4 (Klein et al., 2012; Thomas et al., 2013) . Transcriptional activation of other drug biotransformation genes by PPARα has already been reported for the fatty acid ω -hydroxylase, CYP4A11 (Johnson et al., 2002; Wanders et al., 2011) , several UDPglucuronosyltransferases (Barbier et al., 2003; Senekeo-Effenberger et al., 2007) and some drug transporters (Cheng et al., 2005; Moffit et al., 2006) . Our comparison of ligand-induced gene expression changes mediated by PPARα and the two prototypic xenosensors PXR and CAR further emphasizes the similar target profiles of these three nuclear receptors with respect to the regulation of drug biotransformation genes in the liver (Thomas et al., 2013) .
Thus, being a relatively novel player in the regulation of drug-metabolizing enzymes, PPARα activity in linking regulatory pathways of intermediary and xenobiotic metabolism warrants further studies. exceptional expression and activity of many CYPs relevant for the metabolism of drugs and xenobiotics (Aninat et al., 2006; Guillouzo et al., 2007; Klein et al., 2014) . Our data suggest a significant impact of WNT/β-catenin signaling on basal as well as on inducible expression of the major CYP genes. Moreover, perturbation of the WNT/β-catenin pathway revealed the ancillary role of β -catenin in AhR-, PXR-and CAR-mediated, but an inhibitory role of β -catenin in PPARα-mediated induction of target P450 enzymes (CYP1A, CYP2,CYP3 and CYP4 isoforms). We suggest intricate interactions between WNT/β-catenin signaling, lipid homeostasis, and drug biotransformation capacity that may be of clinical relevance under diseased conditions such as obesity, hepatic steatosis and cancer.
This article has not been copyedited and formatted. The final version may differ from this version. Measurement of P450 enzyme activities. P450 enzyme activities were determined in HepaRG cell culture supernatants using a liquid chromatography with tandem mass spectrometry-based substrate cocktail assay, as described previously (Feidt et al., 2010) .
Western blot analysis. For the protein measurements, 50µg of total cell lysates were electrophoretically separated on a 10% SDS-polyacrylamide gel and subsequently transferred to a nitrocellulose membrane using a Trans-blot semi-dry Fastblot 44 transfer chamber (Biometra, Göttingen, Germany). After blocking with 5% skim milk in TBST membranes were incubated with the primary antibodies in 1% skim milk solution in TBST. For the detection of the levels of proteins of interest, we used a mouse anti-human β -catenin antibody from Becton and Dickinson (Nr. 610154; 1:500 dilution). CYP3A4 protein was detected as described earlier (Wolbold et al., 2003) . For normalization, mouse anti-β-Actin (SigmaAldrich, A5441; 1:500) was used and goat-anti-rabbit-IRD800 (Li-COR, 926-32214;  This article has not been copyedited and formatted. The final version may differ from this version. reported (Thomas et al., 2013) . As an internal control of transfection efficiency, 25 ng of pGL3-TK-Renilla (Promega, Mannheim, Germany) was used. Cells were harvested in reporter "passive" lysis buffer (Promega, Mannheim, Germany) after 48h of incubation, and cell extracts were analyzed for firefly and renilla luciferase activities using Enspire®
Multimode Plate-Reader (Perkin Elmer, Rodgau, Germany) and Luciferase Assay System from P.J.K. GmbH (Kleinblittersdorf, Germany). Firefly luciferase activities were normalized to renilla luciferase activities.
Statistical Methods. For comparisons of two groups, the Student's two-sample t-test (2-tailed) was applied. To identify statistically significant differences between more than two groups, one-way ANOVA with Student-Newman-Keuls post-test was performed.
Measurements of experiments performed in triplicates were averaged prior to analyses.
Statistical significance was defined as p<0.05. All calculations were performed using GraphPad Prism (GraphPad Software Inc., San Diego, CA). Densitometric analyses were performed using the ImageJ software available online from the National Institutes of Health,
USA.
This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Modulation of WNT/β-catenin signaling in HepaRG cells. To follow the consequences of
WNT pathway activation or inhibition on basal and inducible expression of a broad spectrum of CYP isoforms in the human hepatocarcinoma cell line HepaRG, we applied two available strategies in order to either activate or inactivate the pathway, i.e. using stimulation with the canonical natural WNT ligand, WNT3a, and depletion of β -catenin using siRNA. As shown in Impact of WNT/β-catenin pathway modulation on basal CYP expression. Changes in mRNA expression of major P450 enzymes upon WNT/β-catenin pathway stimulation or β -catenin knock-down were investigated in three independent cultures of HepaRG cells (Fig. 2) .
Interestingly, expression levels of only two genes, CYP2E1 gene (2.6-fold) and CYP1A1
(1.8-fold), were significantly upregulated 72 hours following activation of β -catenin, confirming previous observations (Gerbal-Chaloin et al., 2014) . Accordingly, CYP2E1, but not CYP1A1, was more than 50% downregulated by siCAT, suggesting involvement of β -catenin especially in the basal regulation of CYP2E1. In contrast, basal expression of CYP2B6 was significantly increased upon knock-down of β -catenin. However, the observed minor decrease in CYP2B6 expression upon WNT3a treatment was not statistically significant.
Activation of WNT/β-catenin pathway increases AhR-, CAR-and PXR-but inhibits
PPARα-mediated induction of CYP genes. We next asked whether the WNT/β-catenin pathway interferes with the inducibility of P450 enzymes via nuclear receptors during ligandmediated activation by their known agonists. HepaRG cells were treated with the indicated agonists of AhR (Fig. 3A) , CAR (Fig. 3B) , PXR ( Fig. 3C) and PPARα ( for TCDD-mediated upregulation. Similarly, loss of induction was also observed for CARmediated regulation of CYP1A1, CYP1A2, CYP2B6 and CYP3A4 (Fig. 4B) , and PXRmediated regulation of CYP1A1, CYP2B6, CYP2C8 and CYP3A4 (Fig. 4C) . These results confirmed our previous observations using WNT3a treatment (cp. Fig. 3B and C) and further indicated an involvement of β -catenin in the inducibility of these genes via PXR and CAR (cp. Fig. 3B and C) . In contrast, combination of WY14,643 treatment with β -catenin knockdown resulted in the significantly higher induction of CYP1A1, CYP2C8, CYP2E1 and CYP3A genes (Fig. 4D) , which is in line with the WNT3a-mediated effects on PPARα-mediated induction of these CYPs (Fig. 3D) . Interestingly, downregulation of β -catenin did not lead to an increased inducibility of CYP4A11 by PPARα, presumably due to already This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 5A) or siCAT (Fig. 5B ). In line with the mRNA expression profiles, co-induction of PPARα with β -catenin resulted in decreased CYP3A4 protein expression, as compared to WY14,643 treatment alone (Fig.5A , gray bars). Activation of PXR together with β -catenin, however, led to an increased fold induction of CYP3A4 protein compared to the effect of rifampicin alone, confirming the effects at the mRNA level (Fig. 5A , black bars). Correspondingly, knock-down of β -catenin led to increased CYP3A4 protein expression by activated PPARα (Fig. 5B , gray bars) and to more than 50% reduced levels of CYP3A4 protein following treatment with rifampicin ( Fig.   5B , black bars). We could further confirm the opposite roles of β -catenin in the ligandmediated CYP3A4 induction by PXR and PPARα using a luciferase reporter construct containing 8.8kb of an adjacent CYP3A4 promoter transfected in HuH7 cells ( Fig. 5C and   5D ). Thus we could show that β -catenin increased PXR-mediated but inhibited PPARα-mediated induction of CYP3A4 gene and protein expression.
This article has not been copyedited and formatted. The final version may differ from this version. Cyp2e1 (Braeuning et al., 2009; Gougelet et al., 2014) and Cyp1a1/2 mRNAs (Braeuning et al., 2009 (Braeuning et al., , 2011b Vaas et al., 2014) has also been reported. Interestingly, the basal level of the mouse homolog of the human CYP2B6 gene, Cyp2b10, was upregulated in Ctnnb1 knock-out mice (Braeuning et al., 2009; Ganzenberg et al., 2013) , thereby confirming our findings on increased basal expression of CYP2B6 following siRNA-mediated β -catenin knockdown. The lack of major effects of β -catenin on the expression of CYP3A enzymes is also in line with previous results (Gerbal-Chaloin et al., 2014) .
Synergistic activation of target gene expression by β -catenin and the nuclear receptors AhR and CAR has been previously studied in mice as well as in murine cell lines (Braeuning et al., 2009 (Braeuning et al., , 2011a Ganzenberg et al., 2013; Vaas et al., 2014) . An important novel aspect presented in this study is the crosstalk between β -catenin and PPARα in the regulation of different CYPs, especially CYP3A4, the most important CYP isoforms in humans. The role of PPARα in the regulation of drug-metabolizing enzymes from CYP families 1-3 has long been underestimated. However, there are a number of previous reports which demonstrate involvement of PPARα in the regulation of CYP enzymes mediating detoxification of exogenous compounds, including CYP3A4, not only in vitro (Schröder et al., 2011; Klein et al., 2012; Thomas et al., 2013 Thomas et al., , 2014 , but also in vivo (de Keyser et al., 2013; Tsamandouras et al., 2014) . genes. This effect occurs at the transcriptional level at the CYP3A4 promoter and is especially interesting, as the expression of the same gene is synergistically influenced by β -catenin and PXR.
Classically, active β -catenin binds to transcription factors of the TCF (T-cell factor) family to initiate the transcription of target genes, acting as a transcriptional co-activator of the TCF proteins. Synergistic interactions between binding sites for TCF/β-catenin and binding sites for nuclear receptors, e.g. by easier access of the ligand-activated nuclear receptor to a gene promoter which has already bound TCF/β-catenin and therefore changed its chromatin structure, may play a role in the observed interactions between β -catenin and the receptors AhR, CAR, and PXR. Of note, an interaction between a TCF/β-catenin binding site and an
AhR binding site in the human CYP1A1 promoter has been reported (Braeuning et al., 2011b) .
However, so far no unequivocal consensus TCF binding sites were identified within the CYP3A4 promoter, which means that other possible mechanisms should be taken into account. Transcription-inducing effects of β -catenin on certain genes might also be mediated by β -catenin acting as a co-activator of other transcription factors than TCF family members.
For example, it has been published that β -catenin physically interacts with the AhR and modulates the activity of the ligand-activated AhR at its DNA binding sites (Braeuning et al., 2011b ). This effect is thought to be exerted either by β -catenin itself, acting as transcriptional co-activator of the AhR, or by effects of β -catenin on the recruitment of other proteins involved in the transcription process. The AhR is also a direct transcriptional target of β -catenin in human cells (Chesire et al., 2004; Gerbal-Chaloin et al., 2014) . Moreover, recent data point towards a crosstalk of β -catenin and hepatocyte nuclear factor 4α (HNF4α) in the regulation of expression of liver-specific genes in vitro and in vivo, suggesting a further possible mechanism of CYP modulation (Colletti et al., 2009; Gougelet et al., 2014) . HNF4α
plays an important role in the regulation of various CYPs which are also regulated by different xeno-sensing nuclear receptors.
This article has not been copyedited and formatted. The final version may differ from this version. It is more difficult to find mechanistic explanations for the observed inhibitory action of β -catenin on PPARα-dependent effects. An interference via glycogen synthase 3β (GSK) seems possible, as GSK, a key component in canonical WNT signaling, might be also involved in the regulation of PPARα (Pawlak et al., 2014) . However, this scenario would only apply to effects of WNT3a, not for siRNA-mediated silencing of β -catenin, since the latter approach interferes with the WNT pathway downstream of GSK. Moreover, it is not known to which extent the overall activity of GSK is modulated by WNT signaling, since a major part of the regulation during WNT3a-mediated activation of the pathway seems to be related to the dissociation of the GSK-containing multi-protein complex rather than to direct inhibition of the GSK enzyme. The interaction between β -catenin and the AhR has been studied in detail and therefore might provide hints for mechanisms possibly also relevant for the interaction of 
